Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 4/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280007 | 1.00 | DNMT1 (0.59) | DNMT1ADRB1GAAPOLBSMN1; SMN2 | |
| SCHEMBL18183831 | 0.89 | ADRB1 (0.46) | DNMT1ADRB1GAAPOLBSMN1; SMN2 | |
| SCHEMBL23371941 | 0.89 | DNMT1 (0.59) | DNMT1ADRB1POLBSMN1; SMN2PNP | |
| SCHEMBL13252262 | 0.83 | ABL1 (0.53) | GAASMN1; SMN2LMNAADORA3ADORA1 | |
| SCHEMBL9446434 | 0.81 | POLA1 (0.58) | DNMT1ADRB1POLBSMN1; SMN2PNP | |
| SCHEMBL7038107 | 0.81 | POLA1 (0.58) | DNMT1ADRB1POLBSMN1; SMN2PNP | |
| Decitabine SCHEMBL3278641 | 0.81 | DNMT1 (0.66) | DNMT1ADRB1POLBSMN1; SMN2PNP | |
| SCHEMBL7035979 | 0.80 | SLC29A1 (0.57) | ADORA3ADORA1 | |
| SCHEMBL9446435 | 0.80 | SLC29A1 (0.57) | ADORA3ADORA1 | |
| SCHEMBL7905689 | 0.80 | DNMT1 (0.60) | DNMT1ADRB1SMN1; SMN2PNPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000900-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-10933079-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200215092-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. | 2020-07-09 | — | — | US | disclosed |
| US-10456415-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20170035794-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9480698-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9358248-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160130296-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| EP-2944646-A1 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | Astex Pharmaceuticals, Inc. (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-1943264-B1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | ASTEX PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20130236536-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8461123-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20100215729-A1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SUPERGEN, INC. | 2010-08-26 | — | — | US | disclosed |
| US-7700567-B2 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | SUPERGEN, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1943264-A2 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SuperGen, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007041071-A2 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SUPERGEN, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072796-A1 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | ASTEX PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200215092-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885GAA 606/4885 |
| US-20220000900-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885GAA 606/4885 |
| US-20130236536-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885GAA 606/4885 |
| US-10456415-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885GAA 606/4885 |
| US-20160130296-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885GAA 606/4885 |
| US-10933079-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885GAA 606/4885 |
| US-20170035794-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885GAA 606/4885 |
| US-20100215729-A1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885GAA 606/4885 |
| US-20070072796-A1 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | DCTD, DNMT3B, NT5C3B | DNMT1 8/4885ADRB1 3994/4885GAA 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.